EEVIA Stock Overview
Eevia Health Oyj produces and distributes organic bioactive plant extracts in Finland and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Eevia Health Oyj Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr1.54 |
| 52 Week High | kr3.98 |
| 52 Week Low | kr0.83 |
| Beta | 1.24 |
| 1 Month Change | -3.75% |
| 3 Month Change | 10.00% |
| 1 Year Change | -39.37% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -78.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| EEVIA | SE Pharmaceuticals | SE Market | |
|---|---|---|---|
| 7D | 7.7% | 1.0% | 1.4% |
| 1Y | -39.4% | 54.0% | 8.6% |
Return vs Industry: EEVIA underperformed the Swedish Pharmaceuticals industry which returned 55.7% over the past year.
Return vs Market: EEVIA underperformed the Swedish Market which returned 4.4% over the past year.
Price Volatility
| EEVIA volatility | |
|---|---|
| EEVIA Average Weekly Movement | 15.4% |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in SE Market | 13.3% |
| 10% least volatile stocks in SE Market | 3.6% |
Stable Share Price: EEVIA's share price has been volatile over the past 3 months.
Volatility Over Time: EEVIA's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 20 | Stein Ulve | eeviahealth.com |
Eevia Health Oyj produces and distributes organic bioactive plant extracts in Finland and internationally. The company offers bilberry, lingonberry, chaga-mushroom, pine bark, elderberry, and tart cherry extracts. Its products are used in dietary supplements and food products.
Eevia Health Oyj Fundamentals Summary
| EEVIA fundamental statistics | |
|---|---|
| Market cap | kr55.00m |
| Earnings (TTM) | -kr3.21m |
| Revenue (TTM) | kr57.66m |
1.0x
P/S Ratio-17.2x
P/E RatioIs EEVIA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EEVIA income statement (TTM) | |
|---|---|
| Revenue | €4.93m |
| Cost of Revenue | €2.06m |
| Gross Profit | €2.87m |
| Other Expenses | €3.14m |
| Earnings | -€274.00k |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 20, 2024
| Earnings per share (EPS) | -0.0077 |
| Gross Margin | 58.24% |
| Net Profit Margin | -5.56% |
| Debt/Equity Ratio | 19.7% |
How did EEVIA perform over the long term?
See historical performance and comparison